| human | Q5 |
| P496 | ORCID iD | 0000-0002-2529-5664 |
| P27 | country of citizenship | Norway | Q20 |
| P108 | employer | Akershus University Hospital | Q4700653 |
| P734 | family name | Holmøy | Q40479675 |
| Holmøy | Q40479675 | ||
| Holmøy | Q40479675 | ||
| P735 | given name | Trygve | Q660206 |
| Trygve | Q660206 | ||
| P106 | occupation | professor | Q121594 |
| researcher | Q1650915 | ||
| P21 | sex or gender | male | Q6581097 |
| Q43266202 | 25-hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis |
| Q22241950 | A Norse Contribution to the History of Neurological Diseases |
| Q28486389 | A one year follow-up study of natural killer and dendritic cells activities in multiple sclerosis patients receiving glatiramer acetate (GA) |
| Q42280423 | A questionnaire for multinational case-control studies of environmental risk factors in multiple sclerosis (EnvIMS-Q). |
| Q83630660 | A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis |
| Q92719871 | A young woman with seizures, visual impairment, and paralysis |
| Q58486548 | ALS: Cytokine profile in cerebrospinal fluid T‐cell clones |
| Q92572779 | Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis |
| Q84796139 | Alaska, multiple sclerosis, and the vitamin D hypothesis |
| Q28485223 | Alpha-tocopherol and MRI outcomes in multiple sclerosis--association and prediction |
| Q91108949 | An Update on Vitamin D and Disease Activity in Multiple Sclerosis |
| Q38600051 | An update on cladribine for relapsing-remitting multiple sclerosis |
| Q42217719 | Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis |
| Q35843867 | Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis |
| Q47260740 | Assessing amyotrophic lateral sclerosis prevalence in Norway from 2009 to 2015 from compulsory nationwide health registers. |
| Q37768476 | Assessing vitamin D in the central nervous system |
| Q90997797 | B cell depletion in the treatment of multiple sclerosis |
| Q91648303 | B-cell composition in the blood and cerebrospinal fluid of multiple sclerosis patients treated with dimethyl fumarate |
| Q35683879 | Barriers and Facilitators Related to Rehabilitation Stays in Multiple Sclerosis: A Qualitative Study |
| Q40924208 | Body mass index influence interferon-beta treatment response in multiple sclerosis |
| Q44707099 | Body size and the risk of multiple sclerosis in Norway and Italy: the EnvIMS study |
| Q36213665 | Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study |
| Q34429852 | Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study |
| Q93197885 | CD4+ T Cells in the Blood of MS Patients Respond to Predicted Epitopes From B cell Receptors Found in Spinal Fluid |
| Q84623233 | Calprotectin levels in the cerebrospinal fluid reflect disease activity in multiple sclerosis |
| Q87132451 | Can vitamin D reduce inflammation in relapsing-remitting multiple sclerosis? |
| Q43761729 | Cerebrospinal fluid CD4+ T cells from a multiple sclerosis patient cross-recognize Epstein-Barr virus and myelin basic protein |
| Q48140113 | Cerebrospinal fluid T cell clones from patients with multiple sclerosis: recognition of idiotopes on monoclonal IgG secreted by autologous cerebrospinal fluid B cells |
| Q39913279 | Cerebrospinal fluid T cell responses against glutamic acid decarboxylase 65 in patients with stiff person syndrome |
| Q45673107 | Cerebrospinal fluid T cells from multiple sclerosis patients recognize autologous Epstein-Barr virus-transformed B cells |
| Q51146514 | Cost-effectiveness of natalizumab in multiple sclerosis. |
| Q59336507 | Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report |
| Q40690157 | Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosis. |
| Q38438519 | Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial |
| Q81159115 | Environmental risk factors in multiple sclerosis |
| Q26830464 | Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis—association and causation |
| Q82066469 | Expression and functional activity of chemokine receptors in glatiramer acetate-specific T cells isolated from multiple sclerosis patient receiving the drug glatiramer acetate |
| Q90968742 | Extensive Multiple Sclerosis Reactivation after Switching from Fingolimod to Rituximab |
| Q39004378 | Family planning, pregnancy and breastfeeding in multiple sclerosis |
| Q39509517 | Fat-soluble vitamins as disease modulators in multiple sclerosis |
| Q84461329 | Fractures and falls in patients with newly diagnosed clinically isolated syndrome and multiple sclerosis |
| Q43146186 | G127R: A novel SOD1 mutation associated with rapidly evolving ALS and severe pain syndrome |
| Q57822076 | G1m1 predominance of intrathecal virus-specific antibodies in multiple sclerosis |
| Q37550763 | Genetic and molecular approaches to the immunopathogenesis of multiple sclerosis: an update |
| Q91285099 | Genetic testing in amyotrophic lateral sclerosis |
| Q91673342 | Gut microbiota composition during a 12-week intervention with delayed-release dimethyl fumarate in multiple sclerosis - a pilot trial |
| Q93051535 | High BMI is associated with low ALS risk: A population-based study |
| Q36334659 | High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial |
| Q35221540 | High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD8+ T cells |
| Q26747682 | High-throughput sequencing of immune repertoires in multiple sclerosis |
| Q90382676 | Human Cysteine Cathepsins Degrade Immunoglobulin G In Vitro in a Predictable Manner |
| Q34062618 | Identification of human NK17/NK1 cells |
| Q51793479 | Idiotope-specific CD4(+) T cells induce apoptosis of human oligodendrocytes. |
| Q28085605 | Impact of the environment on multiple sclerosis |
| Q42371905 | In Silico Prediction Analysis of Idiotope-Driven T-B Cell Collaboration in Multiple Sclerosis |
| Q42220189 | Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis |
| Q94437363 | Infectious causes of multiple sclerosis |
| Q34999439 | Inflammation markers in multiple sclerosis: CXCL16 reflects and may also predict disease activity |
| Q53174465 | Intrathecal BCR transcriptome in multiple sclerosis versus other neuroinflammation: Equally diverse and compartmentalized, but more mutated, biased and overlapping with the proteome. |
| Q84585375 | Intrathecal levels of vitamin D and IgG in multiple sclerosis |
| Q48168281 | Intravascular large B-cell lymphoma presenting as cerebellar and cerebral infarction |
| Q52978060 | Iron and copper in progressive demyelination--New lessons from Skogholt's disease. |
| Q47606847 | July 2017 ENCALS statement on edaravone |
| Q36432956 | Level of education and multiple sclerosis risk after adjustment for known risk factors: The EnvIMS study |
| Q36334825 | Listeria monocytogenes infection associated with alemtuzumab - - a case for better preventive strategies |
| Q84540513 | Low bone mass in newly diagnosed multiple sclerosis and clinically isolated syndrome |
| Q90836497 | MS-behandlingen blir stadig bedre |
| Q80201396 | Marked differences in prevalence of multiple sclerosis between ethnic groups in Oslo, Norway |
| Q41445665 | Medicine and the arts. Pesta on the Stairs by Theodor Kittelsen. Commentary |
| Q53190953 | Medicine and the arts. Rowing without Oars [excerpt] by Ulla-Carin Lindquist. Commentary. |
| Q33435151 | Medicine and the arts. Three Elling Solheim poems translated by Alison Arderne Philip. Commentary |
| Q84589744 | Modelling and prediction of 25-hydroxyvitamin D levels in Norwegian relapsing-remitting multiple sclerosis patients |
| Q42138439 | Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a |
| Q34418814 | Month of birth and risk of multiple sclerosis: confounding and adjustments |
| Q45274258 | Month of birth as a latitude-dependent risk factor for multiple sclerosis in Norway |
| Q39430589 | Mortality trends of amyotrophic lateral sclerosis in Norway 1951-2014: an age-period-cohort study |
| Q37895312 | Multiple sclerosis, a cause of secondary osteoporosis? What is the evidence and what are the clinical implications? |
| Q37151772 | Multiple sclerosis: immunopathogenesis and controversies in defining the cause |
| Q95271340 | Natural Variation of Vitamin D and Neurofilament Light Chain in Relapsing-Remitting Multiple Sclerosis |
| Q40529011 | Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study |
| Q37098475 | No association of tobacco use and disease activity in multiple sclerosis |
| Q48471497 | Patient satisfaction in rehabilitation of patients with multiple sclerosis |
| Q92458189 | Persistence of intrathecal oligoclonal B cells and IgG in multiple sclerosis |
| Q90597388 | Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a |
| Q89341399 | Re: Familieplanlegging, graviditet og amming ved multippel sklerose |
| Q100431997 | Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder |
| Q42928242 | Reply to comment: Month of birth and risk of multiple sclerosis: confounding and adjustments |
| Q45217370 | Retinol levels are associated with magnetic resonance imaging outcomes in multiple sclerosis |
| Q42246326 | Season of infectious mononucleosis and risk of multiple sclerosis at different latitudes; the EnvIMS Study |
| Q42373792 | Selective intrathecal enrichment of G1m1-positive B cells in multiple sclerosis |
| Q39114204 | Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study |
| Q57464792 | Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis |
| Q36166706 | Severe inflammatory disease activity 14 months after cessation of Natalizumab in a patient with Leber's optic neuropathy and multiple sclerosis - a case report |
| Q88015861 | Severe multiple sclerosis reactivation after gonadotropin treatment |
| Q88128224 | Sex ratio in multiple sclerosis mortality over 65 years; an age-period-cohort analysis in Norway |
| Q44294582 | Sex ratio of multiple sclerosis in persons born from 1930 to 1979 and its relation to latitude in Norway |
| Q85315199 | Shared decision-making in decisions on treatment |
| Q58486547 | Slowly Progressing Amyotrophic Lateral Sclerosis Caused by H46R SOD1 Mutation |
| Q50481101 | Sun exposure and multiple sclerosis risk in Norway and Italy: The EnvIMS study. |
| Q46066191 | Termination of mechanical ventilation in amyotrophic lateral sclerosis |
| Q40946896 | The EnvIMS Study: Design and Methodology of an International Case-Control Study of Environmental Risk Factors in Multiple Sclerosis |
| Q49047601 | The discovery of oligoclonal bands: a 50-year anniversary |
| Q84982933 | The idiotype connection: linking infection and multiple sclerosis |
| Q28295552 | The immunological basis for treatment of stiff person syndrome |
| Q30388273 | The multiple sclerosis susceptibility genes TAGAP and IL2RA are regulated by vitamin D in CD4+ T cells. |
| Q57815026 | The right not to know about amyotrophic lateral sclerosis |
| Q36311036 | Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: The EnvIMS study |
| Q82325386 | Towards individualised multiple sclerosis treatment |
| Q95939835 | Treatment of multiple sclerosis under the COVID-19 pandemic |
| Q41561147 | Unstable terminality: negotiating the meaning of chronicity and terminality in motor neurone disease |
| Q84382890 | Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment |
| Q38049627 | Vitamin D in multiple sclerosis: implications for assessment and treatment |
| Q37921501 | Vitamin D in the healthy and inflamed central nervous system: access and function |
| Q39454682 | Vitamin D sensitive EBNA-1 specific T cells in the cerebrospinal fluid of patients with multiple sclerosis |
| Q41430215 | Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis |
| Q45402871 | Vitamin D status modulates the immune response to Epstein Barr virus: Synergistic effect of risk factors in multiple sclerosis |
| Q85821070 | Vitamin D supplementation and monitoring in multiple sclerosis: who, when and wherefore |
| Q57467842 | Vitamin D supplementation and neurofilament light chain in multiple sclerosis |
| Q40969344 | Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis |
| Q39902201 | Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients. |
| Q85283385 | WT1 and interferon-β-vitamin D association in MS: a longitudinal study |
| Q80799798 | [A rush job and knowledge handling] |
| Q84069835 | [Development of new therapies for multiple sclerosis] |
| Q80482635 | [Incorrect information about treatment of multiple sclerosis from the Knowledge Center] |
| Q58669064 | [Journalism and ethics] |
| Q86228345 | [Re: Unethical of neurologists not to offer patients with multiple sclerosis chemotherapy with autologous stem cell support] |
| Q87963081 | [Re: Vitamin D--how much is enough, and is more better for your health?] |
| Q52753855 | [Stories about life with amyotrophic lateral sclerosis]. |
| Q84780010 | [The problematic difference] |
| Q84190590 | [Treatment of multiple sclerosis] |
| Q88970079 | α-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients |
Search more.